CME: Spotlight: Innovations in MS – Reconsidering the Concept of First-Line High-Efficacy Treatment

Reconsidering the Concept of First-Line, High-Efficacy Treatment

Reconsidering the Concept of First-Line, High-Efficacy Treatment
RestartResume
Which type of therapeutic approach is best for your multiple sclerosis patients: a high-efficacy or escalation approach?

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    In the management of multiple sclerosis there are essentially two therapeutic approaches. The first is a high-efficacy treatment typically reserved for patients with severe disease and a high number of relapses; the second is a slowly intensifying approach known as escalation in which less efficacious treatments are assessed before escalating to a second or third drug. High efficacy treatment comes with a higher risk/reward ratio than does escalation; but escalation can allow disease processes to continue beyond the window of opportunity for highest therapeutic benefit. How can clinicians make the correct choice for their patients?

     

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty
    Prof. Hans-Peter Hartung

    Professor and Chair of the Department of Neurology
    Heinrich-Heine University Dusseldorf
    Medical Director
    Department of Conservative Medicine
    University Hospital Dusseldorf
    Germany

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • John Pirovitz has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the differences between high-efficacy treatments in MS compared to escalation
    • Formulate strategies to identify patients who are likely to benefit from an early-on, high-efficacy approach to treating their MS
  • Target Audience

    This activity is designed to meet the educational needs of neurologists, nurses, nurse practitioners, physician assistants, and other members of the interprofessional team who are involved in the management of patients with multiple sclerosis.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 credits AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

  • Provider

    TOPEC Global designs educational activities based on evidence-based medicine, needs and gaps analyses, learner feedback, and more. Its mission is to serve as an innovative and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and TOPEC Global. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients with Multiple Sclerosis. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement”. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Global Neurology Academy newsletters.
Comprehensive Neurology Education.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Global Neurology Academy…
but how about a more personalized experience?

Register for free